Anavex Life Sciences (AVXL) Proxy filing summary

Executive summary

• Focus on advancing blarcamesine (ANAVEX®2-73) for Alzheimer's, Rett syndrome, and Fragile X syndrome, with regulatory engagement prioritized for these programs.

• Interim leadership established following the termination of the former CEO, with a strong cash position and no long-term debt.

• The 2026 Annual Meeting is contested, with activist investors (PVG Group) nominating an opposing slate of directors.

• The company recommends voting for its six nominees and ratifying Grant Thornton LLP as auditor.

Voting matters and shareholder proposals

• Stockholders will vote to elect six directors and to ratify Grant Thornton LLP as the independent auditor for FY2026.

• The Executive Committee opposes the PVG Group nominees and urges stockholders to disregard their proxy materials.

• Universal proxy card lists both company and PVG Group nominees; only six votes are valid for director election.

• Shareholder proposals for the 2027 meeting must be submitted by April 12, 2027, to be included in proxy materials.

Board of directors and corporate governance

• Board consists of six directors, with a majority deemed independent under Nasdaq rules.

• Board committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined oversight roles.

• Board Chair is independent, and the separation of Chair and CEO roles is maintained.

• Recent leadership changes include the termination of the former CEO for cause and the establishment of an Executive Committee.

• Board diversity is considered, though no formal diversity policy exists.